Vilaprisan for treating uterine fibroids

References

• Bulun S. Uterine fibroids. N Engl J Med. 2013;369:1344–1365.
   PubMed Web of Science ®Google Scholar
• Catherino WH, Parrott E, Segars J. Proceedings from the national institute of child health and human development conference on the uterine fibroid research update workshop. Fertil Steril. 2011;95:9–12.
   PubMed Web of Science ®Google Scholar
• Donnez J, Jadoul P. What are the implications of myomas on fertility? A need for a debate? Hum Reprod. 2002;17:1424–1430.
   PubMed Web of Science ®Google Scholar
• Ben-Nagi J, Miell J, Mavrelos D, et al. Endometrial implantation factors in women with submucous uterine fibroids. Reprod Biomed Online. 2010;21:610–615.
   PubMed Web of Science ®Google Scholar
• Sunkara SK, Khairy M, El-Toukhy T, et al. The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis. Hum Reprod. 2010;25:418–429.
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22:665–686.
   PubMed Web of Science ®Google Scholar
• Linder D, Gartler SM. Glucose-6-phosphate dehydrogenase mosaicism: utilization as a cell marker in the study of leiomyomas. Science. 1965;150:67–69.
   PubMed Web of Science ®Google Scholar
• Ono M, Qiang W, Serna VA, et al. Role of stem cells in human uterine leiomyoma growth. PLoS One 2012;7:e36935.
   PubMed Web of Science ®Google Scholar
• Tanwar PS, Lee HJ, Zhang L, et al. Constitutive activation of beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice. Biol Reprod. 2009;81:545–552.
   PubMed Web of Science ®Google Scholar
• Arici A, Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril. 2000;73:1006–1011.
   PubMed Web of Science ®Google Scholar
• Marsh EE, Bulun SE. Steroid hormones and leiomyomas. Obstet Gynecol Clin North Am. 2006;33:59–67.
   PubMed Web of Science ®Google Scholar
• Parsanezhad ME, Azmoon M, Alborzi S, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010;93:192–198.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ishi K, Serna VA, et al. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010;151:2433–2442.
   PubMed Web of Science ®Google Scholar
• Lamminen S, Rantala I, Helin H, et al. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol Obstet Invest. 1992;34:111–114.
   PubMed Web of Science ®Google Scholar
• Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med. 2015;372:1646–1655.
   PubMed Web of Science ®Google Scholar
• Pérez-López FR, Ornat L, Ceausu I, et al. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79:106–116.
   PubMed Web of Science ®Google Scholar
• Marret H, Fritel X, Ouldamer L, et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur J Obstet Gynecol Reprod Biol. 2012;165:156–164.
   PubMed Web of Science ®Google Scholar
• Mais V, Ajossa S, Guerriero S, et al. Laparoscopic versus abdominal myomectomy: a prospective, randomized trial to evaluate benefits in early outcome. Am J Obstet Gynecol. 1996;174:654–658.
   PubMed Web of Science ®Google Scholar
• Jin C, Hu Y, Chen XC, et al. Laparoscopic versus open myomectomy - a metaanalysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2009;145:14–21.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Laparoscopic uterine power morcellation in hysterectomy and myomectomy, FDA safety communication. 2014 [cited 2016 Jul 4]. Available from: https://wayback.archive-it.org/7993/20170404182209/https:/www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm424443.htm
   Google Scholar
• Bosteels J, Weyers S, Kasius J, et al. Anti-adhesion therapy following operative hysteroscopy for treatment of female subfertility. Cochrane Database Syst Rev. 2015;11:CD011110.
   Google Scholar
• Borah BJ, Nicholson WK, Bradley L, et al. The impact of uterine leiomyomas: a national survey of affected women. Am J Obstet Gynecol. 2013;209:319.e1-319.e20.
   PubMed Web of Science ®Google Scholar
• Qin J, Yang T, Kong F, et al. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case-control studies. Arch GynecolObstet. 2013;288:139–148.
   Google Scholar
• Hoellen F, Griesinger G, Bohlmann MK. Therapeutic drugs in the treatment of symptomatic uterine fibroids. Expert Opin Pharmacother. 2013;14:2079–2085.
   PubMed Web of Science ®Google Scholar
• Duhan N, Madaan S, Sen J. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2013;171:329–332.
   PubMed Web of Science ®Google Scholar
• Song H, Lu D, Navaratnam K, et al. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013;10:CD009505.
   Google Scholar
• Donnez J, Schrurs B, Gillerot S, et al. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril. 1989;51:947–950.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001;Issue 2. Art. No.: CD000547..
   PubMedGoogle Scholar
• Gutmann JN, Corson SL. GnRH agonist therapy before myomectomy or hysterectomy. J Minim Invasive Gynecol. 2005;12:529–537.
   PubMedGoogle Scholar
• Paoletti AM, Serra GG, Cagnacci A, et al. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril. 1996;65:707–710.
   PubMed Web of Science ®Google Scholar
• Lethaby AE, Vollenhoven BJ. An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22:307–331.
   PubMed Web of Science ®Google Scholar
• Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96:1175–1189.
   PubMed Web of Science ®Google Scholar
• Singh SS, Belland L, Leyland N, et al. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids. Am J Obstet Gynecol. 2017;S0002-9378:32697–32702.
   Google Scholar
• Wagenfeld A, Saunders PT, Whitaker L, et al. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin Ther Targets. 2016;20:1045–1054.
   PubMed Web of Science ®Google Scholar
• Xu Q, Ohara N, Liu J, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod. 2008;14:181–191.
   PubMed Web of Science ®Google Scholar
• Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab. 1993;76:513–517.
   PubMed Web of Science ®Google Scholar
• Eisinger SH, Meldrum S, Fiscella K, et al. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101:243–250.
   PubMed Web of Science ®Google Scholar
• Shen Q, Hua Y, Jiang W, et al. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil Steril. 2013;100:1722–1726.
   PubMed Web of Science ®Google Scholar
• Tristan M, Orozco LJ, Steed A, et al. Mifepristone for uterine fibroids. Cochrane Database Syst Rev. 2012;8:CD007687.
   PubMed Web of Science ®Google Scholar
• EPAR summary for the public: Esmya (ulipristal acetate). European Medicines Agency. 2012 [cited 2018 Jan 10]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002041/human_med_001542.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Chwalisz K, Larsen L, Mattia-Goldberg C, et al. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril. 2007;87:1399–1412.
   PubMed Web of Science ®Google Scholar
• Wilkens J, Chwalisz K, Han C, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab. 2008;93:4664–4671.
   PubMed Web of Science ®Google Scholar
• Wiehle R, Goldberg J, Brodniewicz T, et al. Effects of a new progesterone receptor modulator, CDB-4124, on fibroid size and uterine bleeding. US Obstetr Gynaecol. 2008;3:17–20.
   Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409–420.
   PubMed Web of Science ®Google Scholar
• Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366:421–432.
   PubMed Web of Science ®Google Scholar
• Biglia N, Carinelli S, Maiorana A, et al. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Dev Ther. 2014;8:285–292.
   PubMed Web of Science ®Google Scholar
• Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105:165–173.
   PubMed Web of Science ®Google Scholar
• Fauser BC, Donnez J, Bouchard P, et al. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS One 2017;12:e0173523.
   PubMed Web of Science ®Google Scholar
• Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21:591–598.
   PubMed Web of Science ®Google Scholar
• Williams AR, Bergeron C, Barlow DH, et al. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol. 2012;31:556–569.
   PubMed Web of Science ®Google Scholar
• Bouchard P, Chabbert-Buffet N. The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2017;40:105–110.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem compound database. CID=50915138. 2011 [cited 2018 Jan 24]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/50915138
   Google Scholar
• Wagenfeld A, Bone W, Schwede W, et al. BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod. 2013;28:2253–2264.
   PubMed Web of Science ®Google Scholar
• Schütt B, Kaiser A, Schultze-Mosgau M-H, et al. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod. 2016;31:1703–1712.
   PubMed Web of Science ®Google Scholar
• Schultze-Mosgau M-H, Schuett B, Hafner F-T, et al. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women. Int J Clin Pharmacol Ther. 2017;55:16–24.
   PubMed Web of Science ®Google Scholar
• Schultze-Mosgau MH, Höchel J, Prien O, et al. Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential. Clin Pharmacokinet 2018. doi: 10.1007/s40262-017-0607-4.
   PubMedGoogle Scholar
• Schütt B, Schultze-Mosgau MH, Draeger C, et al. Effect of the novel selective progesterone receptor modulator vilaprisan on ovarian activity in healthy women. J Clin Pharmacol. 2018;58:228–239.
   PubMed Web of Science ®Google Scholar
• Bradley L, Ren X, Groettrup-Wolfers E, et al. Results of the asteroid (assess safety and efficacy of vilaprisan in patients with uterine fibroids) 1 study: A phase 2, placebo-controlled dose finding study. Fertil Steril. 2016;106:e95–e96.
   PubMed Web of Science ®Google Scholar
• Seitz C, Bumbuliene Ž, Costa AR, et al. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. Contemp Clin Trials. 2017;55:56–62.
   PubMed Web of Science ®Google Scholar
• Bayer starts phase III study program with vilaprisan in the treatment of symptomatic uterine fibroids. Germany: Investor news. Leverkusen. 2017 [cited 2018 Jan 28]. Available from: https://www.investor.bayer.de/en/nc/news/investor-news/investor-news/bayer-starts-phase-iii-study-program-with-vilaprisan-in-the-treatment-of-symptomatic-uterine-fibroid/
   Google Scholar
• Zimmermann A, Bernuit D, Gerlinger C, et al. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health 2012 Mar 26;12:6.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol. 2001;28(2 Suppl 8):7–14.
   PubMed Web of Science ®Google Scholar
• Turkoski BB. Tired blood. Part 2. Orthop Nur. 2003;22:363–368.
   PubMedGoogle Scholar
• Attardi BJ, Burgenson J, Hild SA, et al. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004;88:277–288.
   PubMed Web of Science ®Google Scholar
• Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril. 2017;108:152–60.e4.
   PubMed Web of Science ®Google Scholar